TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8891015
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Micanol and UVB therapy
Study: 8891015
Drug: Dithranol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithranol treatment (previous studies)
Study: 2000823
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg beta-carotene/d
Study: 2000823
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg beta-carotene/d
Study: 2000823
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg beta-carotene/d
Study: 2000823
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg beta-carotene/d
Study: 27215949
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) + Attention Control (AC)
Study: 27215949
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) + COPD Education (COPD-ED)
Study: 25057878
Drug: Maternal levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal levothyroxine therapy
Study: 15841764
Drug: Commercial MCD
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial MCD and porridge (CC group)
Study: 15841764
Drug: Infants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants with Hb < 110 g/l at 12 months
Study: 15841764
Drug: Infants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants with S-Zn < 10.7 pmol/l at 12 months
Study: 9731046
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine and mitoxantrone as consolidation in study 04/89
Study: 8858275
Drug: Mefloquine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (250 mg on Days 1, 2, 3, 8, 15, 22, and 29)
Study: 8858275
Drug: Alcohol (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (sustained blood concentration of about 0.35 mg.ml-1)
Study: 31294473
Drug: Modifying the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modifying the prosthesis to allow for better oral hygiene (test group)
Study: 31294473
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without modifying the prosthesis (control group)
Study: 22914806
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (ACT = 250 s)
Study: 22914806
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (full heparin dose, ACT = 420 s)
Study: 19845769
Drug: Oxycodone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone with A118G variant allele
Study: 19845769
Drug: Oxycodone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone with C3435T variant allele
Study: 19845769
Drug: Oxycodone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone with G2677T/A variant allele
Study: 15775730
Drug: Exercise (weekly)
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Exercise (weekly)
Study: 10613346
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (20 mg/day)
Study: 7603812
Drug: WI79‐9 virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: WI79‐9 virus vaccine (10^7.3 plaque‐forming units in three oral doses separated by 2 months)
Study: 2262643
Drug: Ryegrass allergen
Normalized name: English ryegrass allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ryegrass allergen (incremental doses applied topically to one eye)
Study: 2262643
Drug: Ryegrass allergen
Normalized name: English ryegrass allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ryegrass allergen (320,000 BU/ml)
Study: 31118
Drug: Heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin + Urokinase (UK)
Study: 31100514
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 16–32 mg/kg/d infusion for 6 days
Study: 23134570
Drug: 2009 pandemic
Normalized name: Influenza A virus H1 2009 pandemic Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009 pandemic (H1N1) vaccine containing 7.5 μg haemagglutinin (HA)
Study: 23134570
Drug: 2009 pandemic
Normalized name: Influenza A virus H1 2009 pandemic Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009 pandemic (H1N1) vaccine containing 15 μg haemagglutinin (HA)
Study: 11305513
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid vaccine (1 ml, 6 Lf units)
Study: 19081697
Drug: MDI/spacer combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI/spacer combination
Study: 16409529
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml x kg(‐1) x h(‐1) of lactated Ringer's solution (superhydration group)
Study: 16409529
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml x kg(‐1) x h(‐1) of lactated Ringer's solution (control group)
Study: 3292596
Drug: Prostacyclin (epoprostenol)
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (epoprostenol) infused intravenously at a dose of up to 5 ng/kg/min for 72 hours with a tapering off period for the last 12 hours.
Study: 3292596
Drug: Placebo infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infused intravenously for the same duration and dosage as prostacyclin.
Study: 30848576
Drug: M2000 (β-D-Mannuronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2000 (β-D-Mannuronic Acid), 500 mg two times a day for 6-8 weeks
Study: 26115578
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol at 80 μg/day
Study: 22000795
Drug: 1-injection group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-injection group (20 mL of 0.75% bupivacaine and 10 mL 98% alcohol)
Study: 22000795
Drug: 2-injection group
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-injection group (20 mL of 0.75% bupivacaine and 10 mL 98% alcohol)
Study: 10740548
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg ml-1 in 0.9% glucose solution
Study: 10740548
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg ml-1 in 8% glucose solution
Study: 27348903
Drug: YANG's pricking‐cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: YANG's pricking‐cupping therapy
Study: 25308231
Drug: VK1 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: VK1 solution
Study: 25308231
Drug: VK1 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: VK1 tablets
Study: 20483024
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive treatment group
Study: 20483024
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment group
Study: 18587731
Drug: Once-weekly intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly intravenous epoetin alfa
Study: 18587731
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing of intravenous epoetin alfa or darbepoetin
Study: 11835638
Drug: Aspirin monotherapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin monotherapy after Carbostent implantation
Study: 11835638
Drug: Combined ticlopidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ticlopidine and aspirin (future comparison group)
Study: 7770254
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (less than 200 mg/day)
Study: 23512912
Drug: Metreleptin (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (physiological doses)
Study: 17511770
Drug: Baclofen 10
Normalized name: baclofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 10 mg three times daily for 4 weeks
Study: 15271125
Drug: Cardiovascular drugs
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drugs
Study: 15271125
Drug: Hormones
Normalized name: Other hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormones
Study: 15271125
Drug: Nonopioid analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonopioid analgesics (predominantly NSAIDs and acetaminophen)
Study: 15271125
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of scheduled medications
Study: 11878715
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium channel blockers and ASA
Study: 11878715
Drug: Diuretics and
Normalized name: Low-ceiling diuretics and potassium-sparing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics and ASA
Study: 9514531
Drug: Amlodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5-10 mg daily for 1 year)
Study: 24716675
Drug: Treatment outcome
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment outcome
Study: 17631948
Drug: Cangrelor IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor IV bolus (30 microg/kg) and a 2-hour infusion (4 microg/kg/min) with 600 mg clopidogrel loading dose
Study: 17631948
Drug: Cangrelor bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor bolus and a 1-hour infusion with 600 mg clopidogrel loading dose
Study: 16777855
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 or 400 mg/day
Study: 16777855
Drug: Sustained-release paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release paracetamol 1330 mg three times a day
Study: 14983653
Drug: Budesonide (1
Normalized name: budesonide (11.beta.,16.alpha.(S))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1 mg/2 ml) diluted with 2 ml isotonic sodium chloride
Study: 14983653
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride (4 ml)
Study: 14983653
Drug: Terbutaline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (5 mg/2 ml) diluted with 2 ml isotonic sodium chloride
Study: 14983653
Drug: Budesonide (1
Normalized name: budesonide (11.beta.,16.alpha.(S))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1 mg/2 ml) and terbutaline (5 mg/2 ml)
Study: 10741293
Drug: Menstruation status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menstruation status after chemotherapy
Study: 9083827
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of 6 mg heroin hydrochloride
Study: 9083827
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of 12 mg heroin hydrochloride
Study: 9083827
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 6 mg heroin hydrochloride
Study: 8366922
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (external insulin pump or three or more daily insulin injections with frequent blood glucose monitoring)
Study: 8366922
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (one or two daily insulin injections)
Study: 3780290
Drug: ergoloid mesylates
Normalized name: Ergoloid Mesylates
DrugBank: Ergoloid mesylate (DB01049)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ergoloid mesylates (1.5 mg 3-times daily)
Study: 31624333
Drug: Creatine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine treatment
Study: 22820908
Drug: ilaprazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ilaprazole (5 mg)
Study: 22820908
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy (ilaprazole 5 mg, clarithromycin 500 mg, amoxicillin 1 g)
Study: 20523253
Drug: diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 10 mg plus clonidine 0.15 mg
Study: 20523253
Drug: midazolam plus
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam plus clonidine 0.15 mg
Study: 18477263
Drug: EXU 3
Normalized name: DRESSING,EXU-DRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXU 3 mg with no passive smoke exposure
Study: 18477263
Drug: EXU 3
Normalized name: DRESSING,EXU-DRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXU 3 mg after passive smoke exposure (atmospheric nicotine levels 75-125 mug m(‐3) for 2 h)
Study: 10858488
Drug: lovastatin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin (20-40 mg/day, titrated to achieve LDL-cholesterol target of < or =110 mg/dL)
Study: 1320987
Drug: Inhaled nedocromil
Normalized name: nedocromil Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nedocromil 4 mg q.i.d. for 8 weeks
Study: 31365799
Drug: Immediate transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate transfusion with 20 ml or 30 ml of whole-blood equivalent per kilogram of body weight
Study: 24700254
Drug: Placebo aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aerosol spray
Study: 23138167
Drug: Cetuximab 500
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 500 mg/m2 every 2 weeks (Group A)
Study: 23138167
Drug: Cetuximab 750
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 750 mg/m2 every 2 weeks (Group B)
Study: 20363366
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol reinduction (400 mg at weeks 0, 2, and 4)
Study: 11948381
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone 400 microg/d
Study: 11948381
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone 800 microg/d
Study: 9465753
Drug: 10% pentastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% pentastarch solution (PS)
Study: 9465753
Drug: Isotonic 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic 0.9% NaCl solution (IS)
Study: 2664372
Drug: FAMTX protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAMTX protocol (high dose methotrexate and 5-fluorouracil combined with adriamycin)
Study: 31151306
Drug: IBD98-M 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBD98-M 0.8 g/day
Study: 31151306
Drug: IBD98-M 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBD98-M 1.2 g/day
Study: 10392645
Drug: Qualified physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qualified physiotherapy (QPT) - additional treatment from a qualified physiotherapist
Study: 10392645
Drug: Assistant physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assistant physiotherapy (APT) - additional treatment from a trained supervised assistant
Study: 10392645
Drug: Additional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional treatment (QPT and APT)
Study: 8675249
Drug: Nifedipine plus
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine plus diltiazem (180 mg/d)
Study: 8675249
Drug: Nifedipine plus
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine plus verapamil (180 mg/d)
Study: 8675249
Drug: Nifedipine alone
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine alone (30 mg/d)
Study: 26329382
Drug: Modafinil (MOD)
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil (MOD) 200 mg daily for 4 weeks
Study: 2139791
Drug: Gel form
Normalized name: Timoptic-XE 0.5 % Gel Forming Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel form etchant
Study: 22381043
Drug: Ritonavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (300 mg twice daily for 3 days)
Study: 20461335
Drug: Standardized task‐oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized task‐oriented therapy with botulinum toxin injections
Study: 20461335
Drug: Standardized task‐oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized task‐oriented therapy without botulinum toxin injections
Study: 15608311
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DMARDs with prednisolone
Study: 2078483
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and low‐dose prednisone (CMFp)
Study: 380909
Drug: Trimipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (75 mg per day)
Study: 31282037
Drug: Anesthetic cream
Normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic cream applied after cryotherapy treatment
Study: 31282037
Drug: Cryotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy treatment without anesthetic cream
Study: 17541571
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral M6G
Study: 17541571
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral M6G
Study: 17541571
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and sulfasalazine coadministered with M6G
Study: 15579192
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogens (CEE) 0.625 mg daily + Desogestrel (DG) 75 microg
Study: 15579192
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogens (CEE) 0.625 mg daily + Medroxyprogesterone (MP) 10 mg
Study: 15579192
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogens (CEE) 0.625 mg daily + Norethisterone (NE) 1 mg
Study: 10526897
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogens (CEE) 0.625 mg daily
Study: 9757170
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/d, increased to 100 mg/d if uncontrolled after 6 weeks
Study: 9757170
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/d + Hydrochlorothiazide 12.5 mg/d if uncontrolled after 6 weeks
Study: 9757170
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/d, increased to 10 mg/d if uncontrolled after 6 weeks
Study: 30275398
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation combined with cognitive stimulation (fortified milk powder and daily learning activities)
Study: 23142798
Drug: Withania somnifera
Normalized name: WITHANIA SOMNIFERA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withania somnifera (2 g every 8 hours during chemotherapy)
Study: 21620782
Drug: Target inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target inhalation mode (TIM)
Study: 18464021
Drug: Estetrol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estetrol 0.1 mg
Study: 18464021
Drug: Estetrol 1
Normalized name: estetrol 14.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estetrol 1 mg
Study: 18464021
Drug: Estetrol 10
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estetrol 10 mg
Study: 18464021
Drug: Estetrol 100
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estetrol 100 mg
Study: 9210746
Drug: Monthly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly maintenance interpersonal psychotherapy with placebo (N = 19)
Study: 9210746
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and supportive medication clinic without interpersonal psychotherapy (N = 28)
Study: 9210746
Drug: Medication clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication clinic without interpersonal psychotherapy (N = 12)
Study: 3297482
Drug: Neo Sampoon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo Sampoon vaginal tablets (60 mg menfegol)